Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. 2008

Marc C Smaldone, and Bruce L Jacobs, and Arlene M Smaldone, and Ronald L Hrebinko
Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA. smaldonemc@upmc.edu

OBJECTIVE We reviewed our experience with partial cystectomy to assess local control and survival rates, and to identify pathologic predictors for recurrence. METHODS From 1995 to 2005, 25 patients with urothelial carcinoma underwent partial cystectomy with curative intent. As protocol, patients with primary solitary muscle-invasive bladder tumors underwent preoperative localized radiotherapy, administration of a single dose of intravesical chemotherapy at the time of partial cystectomy, and postoperative intravesical Bacillus Calmette-Guérin therapy. We reviewed clinical and pathologic data to identify variables associated with disease recurrence. RESULTS We analyzed data from 25 patient records meeting review criteria (72% male, mean age 65.1 +/- 9.8 years). At time of transurethral resection of a bladder tumor (TURBT), all had a solitary primary T2 (68%) or T1HG (32%) lesion with no evidence of carcinoma in situ. At follow-up (mean 45.3 +/- 30.7 months), 5-year recurrence-free, disease-specific, and overall survival rates were 64%, 84%, and 70%, respectively. At a mean of 18.0 +/- 15.6 months, 8% of patients experienced intravesical non-muscle-invasive tumor recurrences and were treated with TURBT and intravesical chemotherapy. Twenty percent recurred with locally advanced tumors or visceral metastasis and were treated with systemic chemotherapy, local resection or cystectomy, or both. On univariate analysis, only tumor size at time of partial cystectomy (P = .03) was significantly associated with tumor recurrence. CONCLUSIONS Partial cystectomy offers adequate control of localized invasive urothelial carcinoma in carefully selected patients with solitary primary tumors. Lifelong follow-up with cystoscopy and abdominal imaging is recommended to detect recurrence.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Marc C Smaldone, and Bruce L Jacobs, and Arlene M Smaldone, and Ronald L Hrebinko
March 2013, BJU international,
Marc C Smaldone, and Bruce L Jacobs, and Arlene M Smaldone, and Ronald L Hrebinko
October 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology,
Marc C Smaldone, and Bruce L Jacobs, and Arlene M Smaldone, and Ronald L Hrebinko
December 2023, Clinical genitourinary cancer,
Marc C Smaldone, and Bruce L Jacobs, and Arlene M Smaldone, and Ronald L Hrebinko
August 2006, World journal of urology,
Marc C Smaldone, and Bruce L Jacobs, and Arlene M Smaldone, and Ronald L Hrebinko
December 2011, International urology and nephrology,
Marc C Smaldone, and Bruce L Jacobs, and Arlene M Smaldone, and Ronald L Hrebinko
September 1995, Journal of surgical oncology,
Marc C Smaldone, and Bruce L Jacobs, and Arlene M Smaldone, and Ronald L Hrebinko
May 2012, European urology,
Marc C Smaldone, and Bruce L Jacobs, and Arlene M Smaldone, and Ronald L Hrebinko
January 2024, Therapeutic advances in urology,
Marc C Smaldone, and Bruce L Jacobs, and Arlene M Smaldone, and Ronald L Hrebinko
June 2022, Urologic oncology,
Marc C Smaldone, and Bruce L Jacobs, and Arlene M Smaldone, and Ronald L Hrebinko
October 2014, Asian journal of surgery,
Copied contents to your clipboard!